SPARC

What does SPARC do?

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical firm focused on developing new drugs and delivery systems, with a market cap of Rs 5,332 Cr. As of March 2025, it reported net sales of 27 Cr and a net loss of 60 Cr.

Overview:<BR>Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems within the Pharmaceuticals & Biotechnology industry, categorized as a Mid Cap.<BR><BR>History:<BR>SPARC was incorporated on March 1, 2006, as an innovative and development company. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 27 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -60 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 5,332 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.23 <BR>Return on Equity: 157.88% <BR>Price to Book: -24.24<BR><BR>Contact Details:<BR>Address: Sun Pharma Advanced Res Centre, Akota Road Akota Vadodara Gujarat : 390020 <BR>Tel: 91-265-2330815/2339257 <BR>Email: secretarial@sparcmail.com <BR>Website: http://www.sparc.life

Has SPARC declared dividend?

No Dividend History Available

Who are the peers of the SPARC?

SPARC's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Supriya Lifesci, Innova Captab, Sequent Sciences, Hikal, and Unichem Labs. SPARC has the lowest 1-year return at -7.64%, while Supriya Lifesci leads with a return of 100.72%.

Peers: The peers of SPARC are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Supriya Lifesci., Innova Captab, Sequent Scien., Hikal, and Unichem Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Supriya Lifesci., and Hikal, while Average management risk is found at Innova Captab and Sequent Scien. Good management risk is present at Divi's Lab., Torrent Pharma, and Unichem Labs. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, SPARC, Supriya Lifesci., Sequent Scien., and Hikal. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Innova Captab, while below average capital structure is found at SPARC and Sequent Scien., and average capital structure is observed at Hikal.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Supriya Lifesci. at 100.72%, while SPARC has the lowest at -7.64%. SPARC's 1-year return is significantly lower than that of its peers. Additionally, the six-month return is negative for SPARC, Sun Pharma.Inds., Torrent Pharma, and Sequent Scien.

Who are in the management team of SPARC?

As of March 2023, the management team of SPARC includes T Rajamannar, Sudhir V Valia, Bhavna Doshi, Ferzaan Engineer, Robert Spiegel, and Dilip S Shanghvi as Chairman (Non-Executive). They are responsible for the company's governance and strategic direction.

As of March 2023, the management team of SPARC includes the following individuals:<BR><BR>1. T Rajamannar - Director<BR>2. Sudhir V Valia - Director<BR>3. Bhavna Doshi - Independent Director<BR>4. Ferzaan Engineer - Independent Director<BR>5. Robert Spiegel - Independent Director<BR>6. Dilip S Shanghvi - Chairman (Non-Executive)<BR><BR>These members play key roles in the governance and strategic direction of the company.

Who are the top shareholders of the SPARC?

The top shareholders of SPARC include Shanghvi Finance Private Ltd with 42.28%, followed by individual investors at 18.99%, and the Sun Pharmaceutical Industries Key Employees Benefit Trust at 3.18%. Mutual funds and foreign institutional investors hold 1.01% and 1.45%, respectively, with no pledged promoter holdings.

The top shareholders of SPARC include the promoters, with Shanghvi Finance Private Ltd holding the largest stake at 42.28%. There are no pledged promoter holdings. In addition, mutual funds hold a total of 1.01% through 10 schemes, while foreign institutional investors (FIIs) account for 1.45% through 31 different FIIs. The highest public shareholder is the Sun Pharmaceutical Industries Key Employees Benefit Trust, which holds 3.18%. Individual investors collectively own 18.99% of the company.

How big is SPARC?

As of 24th July, Sun Pharma Advanced Research Company Ltd has a market capitalization of 5,061.00 Cr, with recent net sales of 71.77 Cr and a net profit loss of 342.51 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Sun Pharma Advanced Research Company Ltd has a market capitalization of 5,061.00 Cr and is classified as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 71.77 Cr, while the sum of Net Profit for the same period shows a loss of 342.51 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025. Shareholder's Funds stand at a loss of 216.95 Cr, and Total Assets are valued at 333.22 Cr.

How has been the historical performance of SPARC?

SPARC has experienced a significant decline in financial performance over the past three years, with net sales dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025, and operating losses worsening from -203.18 crore to -321.35 crore in the same period. Overall, the company's financial metrics indicate ongoing operational challenges.

Answer:<BR>The historical performance of SPARC shows a significant decline in key financial metrics over the past three years, particularly in net sales, operating profit, and net profit.<BR><BR>Breakdown:<BR>SPARC's net sales decreased from 238.78 crore in March 2023 to 75.55 crore in March 2024, and further down to 71.77 crore in March 2025. The total operating income followed a similar trend, dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025. The company faced substantial operating losses, with operating profit (PBDIT) worsening from -203.18 crore in March 2023 to -321.35 crore in March 2025. Profit before tax also reflected this negative trend, moving from -222.58 crore in March 2023 to -342.78 crore in March 2025. Consequently, profit after tax showed a similar decline, falling from -222.58 crore in March 2023 to -342.51 crore in March 2025. The company's total liabilities decreased from 830.13 crore in March 2023 to 333.22 crore in March 2025, while total assets also fell from 830.13 crore to 333.22 crore in the same period. Cash flow from operating activities remained negative, with a cash outflow of -360 crore in March 2025 compared to -429 crore in March 2024. Overall, SPARC's financial performance has deteriorated significantly over the years, indicating ongoing challenges in its operations.

How has been the historical performance of SPARC?

SPARC has faced significant financial challenges over the past three years, with net sales declining from 238.78 Cr in March 2023 to 71.77 Cr in March 2025, and increasing losses reflected in negative operating profit and profit after tax. Despite some cost control efforts, the company has seen a substantial decrease in total assets and liabilities, alongside persistent negative cash flow from operating activities.

Answer:<BR>The historical performance of SPARC shows significant challenges over the past three years, particularly in terms of revenue and profitability.<BR><BR>Breakdown:<BR>SPARC's net sales have declined sharply from 238.78 Cr in March 2023 to 75.55 Cr in March 2024, and further to 71.77 Cr in March 2025. Total operating income followed a similar trend, decreasing from 238.78 Cr in March 2023 to 71.77 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased from 452.84 Cr in March 2023 to 394.91 Cr in March 2025, indicating some cost control efforts. However, operating profit (PBDIT) remained negative, worsening from -203.18 Cr in March 2023 to -321.35 Cr in March 2025. The profit before tax also showed a negative trend, moving from -222.58 Cr in March 2023 to -342.78 Cr in March 2025. Consequently, the profit after tax reflected similar losses, with figures of -222.58 Cr, -387.21 Cr, and -342.51 Cr for the respective years. The company's total liabilities decreased from 830.13 Cr in March 2023 to 333.22 Cr in March 2025, while total assets also fell from 830.13 Cr to 333.22 Cr in the same period. Cash flow from operating activities remained negative, with -360.00 Cr in March 2025, although cash flow from investing activities turned positive at 157.00 Cr. Overall, SPARC's financial performance indicates a trend of declining sales and increasing losses, alongside a significant reduction in total assets and liabilities.

Is SPARC technically bullish or bearish?

As of November 27, 2025, the trend is mildly bearish due to daily moving averages and weekly Bollinger Bands indicating bearish sentiment, despite mixed signals from the MACD and KST, suggesting a cautious approach.

As of 27 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment and the weekly Bollinger Bands also showing a mildly bearish outlook. The MACD on the weekly is mildly bullish, but the monthly remains bearish, creating a mixed signal. The KST aligns with the weekly MACD, being mildly bullish, while the OBV is mildly bearish on the weekly timeframe. Overall, the lack of strong bullish signals and the presence of bearish indicators suggest a cautious approach.

When is the next results date for Sun Pharma Advanced Research Company Ltd?

The next results date for Sun Pharma Advanced Research Company Ltd is 09 February 2026.

The next results date for Sun Pharma Advanced Research Company Ltd is scheduled for 09 February 2026.

Are Sun Pharma Advanced Research Company Ltd latest results good or bad?

Sun Pharma Advanced Research Company Ltd's latest results are poor, showing a net loss of ₹80.42 crores and a 43.33% decline in revenue year-on-year, with a negative book value per share and high operational costs. Investors should be cautious due to the company's deteriorating financial health and rising debt levels.

The latest results for Sun Pharma Advanced Research Company Ltd (SPARC) indicate a challenging financial situation. In Q3 FY26, the company reported a net loss of ₹80.42 crores, which reflects a slight increase in losses of 1.14% year-on-year. Revenue also declined significantly, down 43.33% year-on-year, with net sales recorded at just ₹8.45 crores. <BR><BR>The operating margin was reported at an alarming -670.30%, indicating that the company's operational costs are vastly outpacing its revenues. Furthermore, the book value per share has turned negative at ₹-6.68, highlighting a severe equity erosion. <BR><BR>The financial performance illustrates a company struggling with a high cost structure, particularly with employee expenses that far exceed revenues. The situation is compounded by rising debt levels, with interest costs now at ₹8.78 crores per quarter, adding to the financial strain.<BR><BR>Overall, the results can be characterized as poor, with significant challenges ahead for SPARC in terms of achieving profitability and sustaining operations. Investors should exercise caution given the company's deteriorating financial health and lack of a clear path to recovery.

Should I buy, sell or hold Sun Pharma Advanced Research Company Ltd?

Which are the latest news on SPARC?

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 13-Feb, Sun Pharma Advanced Research Company Ltd's stock is declining, currently priced at Rs 132.10, down 2.11%. The stock has underperformed its sector and shows negative trends across various time frames, compounded by poor financial results and declining investor participation.

As of 13-Feb, Sun Pharma Advanced Research Company Ltd's stock price is falling, currently at Rs 132.10, reflecting a decrease of Rs 2.85 or 2.11%. The stock has been on a downward trend, having underperformed its sector by 1.07% today and experiencing a consecutive decline over the last three days, resulting in a total drop of 6.08% during this period. <BR><BR>The stock's performance over various time frames also indicates a negative trajectory, with a 1-week decline of 5.00% and a 1-month decrease of 2.58%. Year-to-date, the stock has fallen by 1.75%, while it has significantly underperformed over the past year, with a decline of 8.58% compared to a positive return of 8.52% for the Sensex. <BR><BR>Additionally, the company has reported very negative financial results, including a drastic fall in net sales by 43.29% and a negative profit after tax of Rs -143.91 crore, which has grown at a rate of -41.27%. The company's weak long-term fundamentals are further highlighted by a negative book value and a poor EBIT to interest ratio of -141.22, indicating challenges in servicing its debt. <BR><BR>Investor participation is also declining, as evidenced by a 3.36% drop in delivery volume compared to the 5-day average. The stock is trading below all its moving averages, which suggests a bearish trend. Overall, these factors contribute to the stock's current decline.